Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Acute Respiratory Distress Syndrome (ARDS) is the main cause of death from COVID-19. One of the main mechanisms for ARDS is the violent storm of cytokines and chemokines, which cause uncontrolled fatal systemic inflammation by the immune system on the body, with additional multiple organ failure. Mortality in cases of severe ARDS caused by COVID 19 varies significantly between 50 and 90%, basically depending on the age of the patient and the presence of comorbidities. The plasticity of Mesenchymal Stem Cells (MSC) regulates inflammation and immunity. MSC can promote and inhibit an immune response, depending on the dynamics of inflammation and depending on the activation force of the immune system, the types of inflammatory cytokines present, and the effects of immunosuppressants. Essentially, the state of inflammation determines the immunoregulatory fate of MSC. Thus, IV application of AMSCa has been shown to control the inflammatory response in various diseases, such as the graft-versus-host reaction and the ARDS caused by H5NI. The objective of this study is to describe the clinical changes secondary to IV administration of MSC allogenic, in patients with bilateral COVID-19 pneumonia complicated by severe ARDS, with the evaluation of the PaO2 / FiO2 ratio, heart and respiratory rates, and the fever curve. Five patients, of either sex, over 18 years of age, with bilateral pneumonia caused by COVID-19 and severe SIRA that has not improved with the standard management measures used at that time in the care center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent. 1x10(6) xKg will be applied IV. The follow-up of the patient will be for three weeks. PaO2 / FiO2 data, fever, inflammatory markers and immunity will be evaluated. The results will be compared with the historical controls attended at INCMNSZ.
Description: To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the PaO2 / FiO2 ratio.
Measure: Functional Respiratory changes: PaO2 / FiO2 ratio Time: Three weeksDescription: To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the heart rate per minute.
Measure: Clinical cardiac changes: Heart rate per minute Time: Three weeksDescription: To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the respiratory rate per minute.
Measure: Clinical Respiratory Changes: Respiratory rate per minute Time: Three weeksDescription: To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the fever curve in degrees centigrade.
Measure: Changes in body temperature Time: Three weeksDescription: To assess the effect of the proposed treatment on the total Leukocytes
Measure: General biochemical changes in Leukocytes Time: Three weeksDescription: To assess the effect of the proposed treatment on absolute lymphocytes
Measure: General biochemical changes on lymphocytes Time: Three weeksDescription: To assess the effect of the proposed treatment on total platelets
Measure: General biochemical changes on platelets Time: Three weeksDescription: To assess the effect of the proposed treatment on serum fibrinogen
Measure: General biochemical changes on fibrinogen Time: Three weeksDescription: To assess the effect of the proposed treatment on procalcitonin
Measure: General biochemical changes on pocalcitonin Time: Three weeksDescription: To assess the effect of the proposed treatment on ferritin
Measure: General biochemical changes on ferritin Time: Three weeksDescription: To assess the effect of the proposed treatment on D-dimer
Measure: General biochemical changes on D-dimer Time: Three weeksDescription: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of C-reactive protein
Measure: Changes on inflammatory C-reactive protein Time: Three weeksDescription: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of TNFa in plasma.
Measure: Cahnges on Inflammatory cytokine TNFa Time: Three weeksDescription: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL10 in plasma.
Measure: Changes on Inflammatory cytokine IL10 Time: Three weeksDescription: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL1 in plasma.
Measure: Changes on Inflammatory cytokine IL1 Time: Three weeksDescription: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL6 in plasma.
Measure: Changes on Inflammatory cytokine IL6 Time: Three weeksDescription: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of IL17 in plasma
Measure: Changes on Inflammatory cytokine IL 17 Time: Three weeksDescription: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of VEGF in plasma
Measure: Changes on VEGF Time: Three weeksDescription: Assess the radiological evolution of the proposed treatment through simple chest CT
Measure: Radiological Changes Time: Three weeksDescription: Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: regulatory T cells
Measure: Immunological changes on T cell Time: Three weeksDescription: Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: dendritic cells
Measure: Immunological changes on Dendritic cells Time: Three weeksDescription: Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: CD4 + T
Measure: Immunological changes on CD4+ T Time: Three weeksDescription: Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: CD8 + T
Measure: Immunological changes on CD8+ T Time: Three weeksDescription: Evaluate immune system improvement with mass cytometry to analyze patients' immune cells: NK cells
Measure: Immunological changes on NK cell Time: Three weeksDescription: Evaluate the safety of the proposed treatment (allergic reactions and / or infection)
Measure: Adverse events Time: Three weeksDescription: To assess the negativization of the SARS-Cov2 PCR RNA detection test
Measure: RNA detection by SARS-Cov2 PCR Time: Three weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports